Parabilis Medicines, Inc.
PBLS
$38.76
-$1.01-2.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | 148.00K | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 148.00K | -- | -- | ||
| Cost of Revenue | 39.38M | -- | 30.13M | ||
| Gross Profit | -39.23M | -- | -30.13M | ||
| SG&A Expenses | 11.66M | 9.70M | 5.34M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 51.03M | 47.45M | 35.46M | ||
| Operating Income | -50.89M | -47.45M | -35.46M | ||
| Income Before Tax | -52.46M | -45.32M | -34.81M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -52.46M | -45.32M | -34.81M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -52.46M | -45.32M | -34.81M | ||
| EBIT | -50.89M | -47.45M | -35.46M | ||
| EBITDA | -50.29M | -46.85M | -34.85M | ||
| EPS Basic | -2.32 | -22.47 | -22.28 | ||
| Normalized Basic EPS | -1.13 | -8.98 | -10.78 | ||
| EPS Diluted | -2.32 | -22.47 | -22.28 | ||
| Normalized Diluted EPS | -1.13 | -8.98 | -10.78 | ||
| Average Basic Shares Outstanding | 28.91M | 3.15M | 2.02M | ||
| Average Diluted Shares Outstanding | 28.91M | 3.15M | 2.02M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||